Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha-1 (Zadaxin) perioperative immunotherapy in colorectal cancer
ChiCTR2200055819Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2022
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of thymosin alpha 1 in colorectal cancer (CRC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: CD4/CD8 ratio, C-reactive protein (CRP) and 5 more. Started Jan 2022; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200055819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055819.